Search
Eprodisate
go.drugbank.com/drugs/DB06405InvestigationalEprodisate slows the decline of renal function in AA amyloidosis.
PI-0824
go.drugbank.com/drugs/DB05516InvestigationalThe goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only on the disease causing components of the immune system. … People with PV produce antibodies that attack the cells of the skin, resulting in blisters which, if left untreated, can lead to devastating infections and discomfort.
Digitoxin
go.drugbank.com/drugs/DB01396ApprovedWithdrawnIt has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
Trimetrexate
go.drugbank.com/drugs/DB01157ApprovedA nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. M...
Bambermycins
go.drugbank.com/drugs/DB11377ExperimentalVet approvedThey are used as an additive in food ingested by chickens and swine. The bambermycin complex of antibiotics consists primarily of moenomycins A and C.
RPI-MN
go.drugbank.com/drugs/DB17957Experimental[A260132] Being developed by Nutra Pharma under the trade name PEPTERON, it is being investigated for the treatment of neurological and immune disorders.[L47107]
Q-Derp1
go.drugbank.com/drugs/DB05857ExperimentalQ-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.
ADH-1
go.drugbank.com/drugs/DB05485InvestigationalPoorly differentiated, highly invasive carcinomas are characterized by over-expression of N-cadherin (as opposed to E-cadherin). … Adherex's biotechnology compound, ADH-1, targets N-cadherin, a protein present on certain tumor cells and established tumor blood vessels.
Synonyms: l-cysteinamide, n-acetyl-l-cysteinyl-l-histidyl-l-alanyl-l-valyl-, cyclic (1-5)-disulfideMetiamide
go.drugbank.com/drugs/DB08805ExperimentalIt was an intermediate product on the path to developing cimetidine.
AG0301-COVID19
go.drugbank.com/drugs/DB15856InvestigationalAG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. … On September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of Phase 1/2 clinical studies (NCT04463472).